In the last trading session, 1.38 million Emergent Biosolutions Inc (NYSE:EBS) shares changed hands as the company’s beta touched 2.13. With the company’s per share price at $6.73 changed hands at $0.09 or 1.36% during last session, the market valuation stood at $365.28M. EBS’s last price was a discount, traded about -124.37% off its 52-week high of $15.10. The share price had its 52-week low at $4.02, which suggests the last value was 40.27% up since then.
Analysts gave the Emergent Biosolutions Inc (EBS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended EBS as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Emergent Biosolutions Inc’s EPS for the current quarter is expected to be -0.03.
Emergent Biosolutions Inc (NYSE:EBS) trade information
Instantly EBS was in green as seen at the end of in last trading. With action 15.24%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -29.60%, with the 5-day performance at 15.24% in the green. However, in the 30-day time frame, Emergent Biosolutions Inc (NYSE:EBS) is 45.67% up.
The consensus price target for the stock as assigned by Wall Street analysts is 51.5, meaning bulls need an upside of 86.93% from its current market value. According to analyst projections, EBS’s forecast low is 38 with 65 as the target high. To hit the forecast high, the stock’s price needs a -865.82% plunge from its current level, while the stock would need to soar -464.64% for it to hit the projected low.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Year-over-year growth is forecast to reach -21.87% down from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 148.55M. 2 analysts are of the opinion that Emergent Biosolutions Inc’s revenue for the current quarter will be 212.55M. The company’s revenue for the corresponding quarters a year ago was 254.7M and 293.8M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -41.68%. The estimates for the next quarter sales put growth at -27.65%.
The 2025 estimates are for Emergent Biosolutions Inc earnings to increase by 469.57%.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.97% or 3.67 million shares worth $25.0 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were American Century ETF Trust-Avantis U.S. Small Cap Value ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. With 1.94 shares estimated at $13.06 million under it, the former controlled 3.58% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.83% of the shares, roughly 1.54 shares worth around $10.34 million.
